Interest of the Reborn® Doll as a TO in the Care of Residents With Alzheimer's Disease or a Related Disorder

Dementia Alzheimers Clinical Trial

— PROTMA  

Official title:

Interest of the Reborn® Doll as a Therapeutic Object in the Care of Residents With Alzheimer's Disease or a Related Disorder : Pilote Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06396377
• Other study ID #: RBHP 2023 MARTIN
• Secondary ID: 2023-A00383-42
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 1, 2024
• Est. completion date: January 2025

Study information

• Verified date: April 2024
• Source: University Hospital, Clermont-Ferrand
• Contact: Lise Laclautre
• Phone: +33473754963
• Email: promo_interne_drci[@]chu-clermontferrand.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the benefits of the Reborn®doll as an OT for the care of residents with Alzheimer's disease or related disorders, by assessing the frequency of resident agitation. The secondary objectives are to study the frequency of treatments, evaluate the average time of exposure to the Reborn® doll, study the behavior of the residents, study the interest of this therapeutic workshop, thanks to an evaluation grid and finally study the repercussions of this OT on the nursing staff.

Description:

Dementia affects 50 million people worldwide, and this number is set to continue rising as the population ages. Indeed, the World Health Organization (WHO) expects this number to reach 82 million by 2030. At present, there is no cure for dementia. In order to limit the need for drug treatments for dementia-related symptoms (agitation, aggression), non-drug treatments can be used to improve residents' lives and soothe them. In the late 1960s, researchers turned their attention to non-medication therapies (snozelen concept, animal mediation, calinotherapy, Tovertafel, Carpe Diem, doll'therapy). This doll is used by caregivers to calm anxiety attacks, aggression or apathy in residents with MND. The doll helps to calm the elderly by focusing them on an object. Several studies have shown that residents are calmed and feel valued by taking care of the doll. This also helps to avoid physical or chemical restraints, as well as the use of drug therapies in cases of agitation. Reborn® dolls are an evolution of Doll'therappy.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 24
• Est. completion date: January 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Resident aged 65 and over
• Moderate to severe cognitive impairment diagnosed using the NPI-ES scale
• Behavioral disorders (agitation, aggression, anxiety, apathy) assessed using the NPI-ES scale
• Covered by a social security plan
• Written consent of representative (tutor/ curator/trusted person)

Exclusion Criteria:

• Resident or representative refusing to participate
• Resident under judicial protection

Related Conditions & MeSH terms

• Alzheimer Disease
• Dementia Alzheimers

Intervention

Device:
• Reborn doll (Therapeutic object - OT)
If the resident is randomized to the intervention group, the investigating team will give the Reborn®doll to the resident, during a 45-minute to 1-hour workshop, twice a week for 3 weeks. The OTs, wrapped in a blanket, are presented to the residents by a member of the investigative team trained in reborning , in the resident's room. If the resident is not in his/her room, he/she will be taken back to receive his/her doll. In the case of double rooms, it will be necessary to assess whether or not to leave the room-mate in the room, in order to limit the loss of reference points for the resident concerned by the study. The caregiver lets the resident appropriate and recognize the OT, so that he or she can find meaning in it and awaken his or her sensory memory.In total, the patient will be exposed to OT 6 times.

Locations

Country	Name	City	State
France	CHU de Clermont-Ferrand	Clermont-Ferrand

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Episodes of resident agitation using the Cohen Mansfield scale	The number of episodes of agitation will be collected weekly by the nursing assistant or nurse in charge of monitoring, by compiling the events reported on a resident monitoring document with the time of recording.; The characterization of these episodes should correspond to one of the items on the Cohen Mansfield scale. Two consecutive episodes cannot be counted if they are less than one hour apart (and will therefore be counted as a single event). Follow-up should be strictly identical, whether the resident belongs to the intervention group or the control group.	During the study period (4 weeks)
Secondary	Factors that can affect doll benefits: gender, age, pathology, Charlson Comorbidity Index, doll identifier.		Inclusion
Secondary	Drug treatments	Medication during study period (name/posology) if applicable (daily record)	During the study period (4 weeks)
Secondary	Average exposure time to Reborn®dolls	Average exposure time to Reborn®dolls in minutes	During the study period (4 weeks)
Secondary	Therapeutic evaluation scale	Therapeutic evaluation grid only on days when residents are in possession of the OT on the Crossway computerized file	During the study period (4 weeks)
Secondary	Quality of working life questionnaire	Quality of working life questionnaire to be completed by nursing staff on the Friday of the observation week, and on the last Friday (last day of the study).	During the study period (4 weeks)
Secondary	Resident behavior following OT withdrawal	Resident behavior following OT withdrawal (for experimental group). Observation of the care team.	During the study period (4 weeks)
Secondary	Resident behavior after OT exposure	Resident behavior after OT exposure. Observation of the care team.	During the study period (4 weeks)